Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
Strategies for Delivering Anti-HIV Therapy in South Africa
- Conditions
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2007-09-18
- Target Recruit Count
- 813
- Registration Number
- NCT00080522
- Locations
- 🇿🇦
University of the Witwatersrand/Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa
🇿🇦University of Cape Town/Masiphumelele, Cape Town, South Peninsula, South Africa
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 3526
- Registration Number
- NCT00074581
- Locations
- 🇺🇸
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
🇧🇼Gaborone CRS, Gaborone, Botswana
🇧🇷Hospital Geral de Nova Iguaçu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
- Conditions
- First Posted Date
- 2003-02-20
- Last Posted Date
- 2014-10-15
- Target Recruit Count
- 283
- Registration Number
- NCT00055120
- Locations
- 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸Santa Clara Valley Medical Center, Stanford, California, United States
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 775
- Registration Number
- NCT00050895
- Locations
- 🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00001688
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
- Conditions
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 402
- Registration Number
- NCT00036452
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸MetroHealth CRS, Cleveland, Ohio, United States
🇺🇸Pitt CRS, Pittsburgh, Pennsylvania, United States
Study of Anti-HIV Therapy Intensification
- Conditions
- First Posted Date
- 2002-04-23
- Last Posted Date
- 2012-05-18
- Target Recruit Count
- 22
- Registration Number
- NCT00034086
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 110
- Registration Number
- NCT00000923
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.